Features of vulnerable plaques and clinical outcome of UA/NSTEMI: Relationship with matrix metalloproteinase functional polymorphisms

Atherosclerosis

Volumn 215, Issue 1, 2011, Pages 153-159

  Fiotti, Nicola ^a   Moretti, Michèle Emilia ^b   Bussani, Rossana ^a   Altamura, Nicola ^a   Zamolo, Francesca ^a   Gerloni, Riccardo ^a   Ukovich, Laura ^a   Ober, Elisa ^a   Silvestri, Furio ^a   Grassi, Gabriele ^a   Adovasio, Roberto ^a   Giansante, Carlo ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

^b ASS 6 Friuli Occidentale   (Italy)

Author keywords

Acute coronary syndromes; Genetic polymorphisms; Matrix metalloproteinase; Stroke; Vulnerable plaque

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GELATINASE B; HEPARIN; INTERSTITIAL COLLAGENASE; NITRATE; STROMELYSIN; VASODILATOR AGENT;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CAROTID ATHEROSCLEROSIS; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HETEROZYGOTE; HUMAN; INDEL MUTATION; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE MARKER; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PRIORITY JOURNAL; STROKE; UNSTABLE ANGINA PECTORIS;

AGED; ANGINA, UNSTABLE; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; MYOCARDIAL INFARCTION; PLAQUE, ATHEROSCLEROTIC; POLYMORPHISM, GENETIC; STROKE;

EID: 79952103886     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.12.010     Document Type: Article

References (32)

1. Braunwald E., Antman E.M., Beasley J.W., et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction - summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 2002, 40:1366-1374.
2. Virmani R., Burke A.P., Kolodgie F.D., et al. Pathology of the thin-cap fibroatheroma: a type of vulnerable plaque. J Interv Cardiol 2003, 16:267-272.
3. Ding S., Zhang M., Zhao Y., et al. The role of carotid plaque vulnerability and inflammation in the pathogenesis of acute ischemic stroke. Am J Med Sci 2008, 336:27-31.
4. Giansante C., Fiotti N., Di Chiara A., et al. In-hospital outcome of patients with acute coronary syndrome: relationship with inflammation and remodeling markers. J Cardiovasc Med (Hagerstown) 2007, 8:602-607.
5. Galis Z.S., Sukhova G.K., Lark M.W., et al. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994, 94:2493-2503.
6. Rutter J.L., Mitchell T.I., Buttice G., et al. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription. Cancer Res 1998, 58:5321-5325.
7. Ye S., Watts G.F., Mandalia S., et al. Preliminary report: genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis. Br Heart J 1995, 73:209-215.
8. Shimajiri S., Arima N., Tanimoto A., et al. Shortened microsatellite d(CA)21 sequence down-regulates promoter activity of matrix metalloproteinase 9 gene. FEBS Lett 1999, 455:70-74.
9. Cao Z., Li C., Xiang J. Effect of matrix metalloproteinase-1 promoter genotype on interleukin-1beta-induced matrix metalloproteinase-1 production in human periodontal ligament cells. J Periodontal Res 2009.
10. Fornoni A., Wang Y., Lenz O., et al. Association of a decreased number of d(CA) repeats in the matrix metalloproteinase-9 promoter with glomerulosclerosis susceptibility in mice. J Am Soc Nephrol 2002, 13:2068-2076.
11. Fukuda D., Shimada K., Tanaka A., et al. Comparison of levels of serum matrix metalloproteinase-9 in patients with acute myocardial infarction versus unstable angina pectoris versus stable angina pectoris. Am J Cardiol 2006, 97:175-180.
12. Zhu C., Odeberg J., Hamsten A., et al. Allele-specific MMP-3 transcription under in vivo conditions. Biochem Biophys Res Commun 2006, 348:1150-1156.
13. Abilleira S., Bevan S., Markus H.S. The role of genetic variants of matrix metalloproteinases in coronary and carotid atherosclerosis. J Med Genet 2006, 43:897-901.
14. Nojiri T., Morita H., Imai Y., et al. Genetic variations of matrix metalloproteinase-1 and -3 promoter regions and their associations with susceptibility to myocardial infarction in Japanese. Int J Cardiol 2003, 92:181-186.
15. Pearce E., Tregouet D.A., Samnegard A. Haplotype effect of the matrix metalloproteinase-1 gene on risk of myocardial infarction. Circ Res 2005, 97:1070-1076.
16. Ghaderian S.M., Akbarzadeh N.R., Tabatabaei Panah A.S., et al. Genetic polymorphisms and plasma levels of matrix metalloproteinases and their relationships with developing acute myocardial infarction. Coron Artery Dis 2010, 21:330-335.
17. Yoon S., Tromp G., Vongpunsawad S., et al. Genetic analysis of MMP3 MMP9, and PAI-1 in Finnish patients with abdominal aortic or intracranial aneurysms. Biochem Biophys Res Commun 1999, 265:563-568.
18. Fiotti N., Altamura N., Fisicaro M., et al. MMP-9 microsatellite polymorphism and susceptibility to carotid arteries atherosclerosis. Arterioscler Thromb Vasc Biol 2006, 26:1330-1336.
19. Nikkari S.T., O'Brien K.D., Ferguson M., et al. Interstitial collagenase (MMP-1) expression in human carotid atherosclerosis. Circulation 1995, 92:1393-1398.
20. Lemaitre V., O'Byrne T.K., Borczuk A.C., et al. ApoE knockout mice expressing human matrix metalloproteinase-1 in macrophages have less advanced atherosclerosis. J Clin Invest 2001, 107:1227-1234.
21. Ghaderian S.M., Akbarzadeh N.R., Tabatabaei Panah A.S., et al. Matrix metalloproteinase: investigation from gene to protein as effective factor in myocardial infarction. J Thromb Thrombolysis 2010.
22. Oettgen P. Regulation of vascular inflammation and remodeling by ETS factors. Circ Res 2006, 99:1159-1166.
23. Nelson K.K., Subbaram S., Connor K.M., et al. Redox-dependent matrix metalloproteinase-1 expression is regulated by JNK through Ets and AP-1 promoter motifs. J Biol Chem 2006, 281:14100-14110.
24. Miwa K., Nakashima H., Aoki M., et al. Inhibition of ets, an essential transcription factor for angiogenesis, to prevent the development of abdominal aortic aneurysm in a rat model. Gene Ther 2005, 12:1109-1118.
25. Newby A.C., Johnson J.L. Genetic strategies to elucidate the roles of matrix metalloproteinases in atherosclerotic plaque growth and stability. Circ Res 2005, 97:958-960.
26. Limb G.A., Matter K., Murphy G., et al. Matrix metalloproteinase-1 associates with intracellular organelles and confers resistance to lamin A/C degradation during apoptosis. Am J Pathol 2005, 166:1555-1563.
27. Johnson J.L., George S.J., Newby A.C., et al. Divergent effects of matrix metalloproteinases 3, 7, 9, and 12 on atherosclerotic plaque stability in mouse brachiocephalic arteries. Proc Natl Acad Sci USA 2005, 102:15575-15580.
28. Zhang B., Dhillon S., Geary I., et al. Polymorphisms in matrix metalloproteinase-1, -3 -9, and -12 genes in relation to subarachnoid hemorrhage. Stroke 2001, 32:2198-2202.
29. Fiotti N., Altamura N., Orlando C., et al. Metalloproteinases-2 -9 and TIMP-1 expression in stable and unstable coronary plaques undergoing PCI. Int J Cardiol 2008, 127:350-357.
30. Ducharme A., Frantz S., Aikawa M., et al. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest 2000, 106:55-62.
31. Tamura F., Nakagawa R., Akuta T., et al. Proapoptotic effect of proteolytic activation of matrix metalloproteinases by Streptococcus pyogenes thiol proteinase (Streptococcus pyrogenic exotoxin B). Infect Immun 2004, 72:4836-4847.
32. Gautier E.L., Huby T., Witztum J.L., et al. Macrophage apoptosis exerts divergent effects on atherogenesis as a function of lesion stage. Circulation 2009, 119:1795-1804.